INT69310

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1997
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 10
Total Number 10
Disease Relevance 7.83
Pain Relevance 5.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (IL1A) cytosol (IL1A) extracellular space (IL1A)
extracellular region (IL1A)
Anatomy Link Frequency
macrophage 1
monocyte 1
connective tissue 1
IL2R 1
IL1A (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 22 100.00 Very High Very High Very High
Inflammatory response 5 100.00 Very High Very High Very High
antagonist 3 100.00 Very High Very High Very High
cINOD 7 99.78 Very High Very High Very High
dexamethasone 8 99.38 Very High Very High Very High
Hyperalgesia 3 99.32 Very High Very High Very High
allodynia 6 97.28 Very High Very High Very High
Arthritis 106 95.88 Very High Very High Very High
cytokine 62 95.76 Very High Very High Very High
peripheral neuropathy 1 95.76 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 71 100.00 Very High Very High Very High
Pain 20 100.00 Very High Very High Very High
Hyperalgesia 6 99.32 Very High Very High Very High
Neuropathic Pain 6 97.28 Very High Very High Very High
Cancer 31 96.80 Very High Very High Very High
Rheumatoid Arthritis 106 95.88 Very High Very High Very High
Peripheral Neuropathy 1 95.76 Very High Very High Very High
Solid Tumor 4 95.72 Very High Very High Very High
Apoptosis 25 94.00 High High
Endometriosis 252 93.20 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Cohorts of patients received rhuIL-1 alpha in doses of 0.1-10 micrograms/m2 for 4 days by subcutaneous injection prior to ICF chemotherapy (ifosfamide, 2 g/m2/day x 3, carboplatin targeted to an area under the curve of 8 mg/ml x min on day 1, and etoposide, 100 mg/m2 daily for 3 days).
Negative_regulation (received) of rhuIL-1 alpha
1) Confidence 0.43 Published 1997 Journal Med. Pediatr. Oncol. Section Abstract Doc Link 9143391 Disease Relevance 0.67 Pain Relevance 0.05
Patients were randomized to receive rhuIL-1 alpha before either the first or second course of therapy.
Negative_regulation (receive) of rhuIL-1 alpha
2) Confidence 0.43 Published 1997 Journal Med. Pediatr. Oncol. Section Abstract Doc Link 9143391 Disease Relevance 0.83 Pain Relevance 0.07
It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity.
Negative_regulation (inhibition) of IL1 associated with cinod
3) Confidence 0.42 Published 1999 Journal Z Rheumatol Section Abstract Doc Link 10441838 Disease Relevance 0.62 Pain Relevance 0.81
The Bangladesh and Taiwan studies and our U.S. study all observed a decrease in inflammatory response pathway members, including interleukins such as IL2R (Argos et al. 2006) and IL1 ?
Negative_regulation (decrease) of IL1 in IL2R associated with inflammatory response
4) Confidence 0.31 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2290973 Disease Relevance 0.59 Pain Relevance 0.08
DEX was also found to be a potent inhibitor of IL1-induced expression of the IL6 gene in connective tissue-type cells from the synovium of patients with RA.
Negative_regulation (inhibitor) of IL1 in connective tissue associated with dexamethasone and arthritis
5) Confidence 0.29 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2855702 Disease Relevance 0.85 Pain Relevance 0.80
The addition of dexamethasone (required to reduce pain with the highest doses) inhibited IL-1alpha and enhanced the induction of IL-1ra by VRCTC-310-Onco.
Negative_regulation (inhibited) of IL-1alpha associated with pain and dexamethasone
6) Confidence 0.15 Published 2001 Journal Immunol. Lett. Section Abstract Doc Link 11137138 Disease Relevance 0.34 Pain Relevance 0.34
Danazol inhibits interleukin-1 (IL1) and TNF production by monocytes in a dose-dependent manner [74] and suppresses macrophage/monocyte-mediated cytotoxicity of susceptible target cells in women with mild endometriosis [75].
Negative_regulation (inhibits) of IL1 in macrophage associated with endometriosis
7) Confidence 0.12 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC305339 Disease Relevance 1.04 Pain Relevance 0.43
Danazol inhibits interleukin-1 (IL1) and TNF production by monocytes in a dose-dependent manner [74] and suppresses macrophage/monocyte-mediated cytotoxicity of susceptible target cells in women with mild endometriosis [75].
Negative_regulation (inhibits) of IL1 in monocyte associated with endometriosis
8) Confidence 0.04 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC305339 Disease Relevance 1.04 Pain Relevance 0.43
Blockade of interleukin-1 (IL1) inhibited hyperalgesia induced by both sPLA2s, while leaving allodynia unaffected.
Negative_regulation (Blockade) of interleukin-1 associated with hyperalgesia and allodynia
9) Confidence 0.01 Published 2004 Journal Pain Section Abstract Doc Link 15327810 Disease Relevance 1.11 Pain Relevance 1.09
The present experiments examine whether fractalkine-induced pain enhancement is altered by a microglial inhibitor (minocycline) and/or by antagonists/inhibitors of three putative glial products implicated in pain enhancement: interleukin-1 (IL1), interleukin-6 (IL6) and nitric oxide (NO).
Negative_regulation (inhibitor) of interleukin-1 associated with pain and antagonist
10) Confidence 0.01 Published 2005 Journal Eur. J. Neurosci. Section Abstract Doc Link 16324111 Disease Relevance 0.75 Pain Relevance 0.94

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox